Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.

MLA

Kuo, Tracy C., et al. “Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti-Tumor Activity.” Journal of Hematology & Oncology, vol. 13, no. 1, Nov. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s13045-020-00989-w.

APA

Kuo, T. C., Chen, A., Harrabi, O., Sockolosky, J. T., Zhang, A., Sangalang, E., Doyle, L. V., Kauder, S. E., Fontaine, D., Bollini, S., Han, B., Fu, Y.-X., Sim, J., Pons, J., & Wan, H. I. (2020). Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology, 13(1), N.PAG. https://doi.org/10.1186/s13045-020-00989-w

Chicago

Kuo, Tracy C., Amy Chen, Ons Harrabi, Jonathan T. Sockolosky, Anli Zhang, Emma Sangalang, Laura V. Doyle, et al. 2020. “Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti-Tumor Activity.” Journal of Hematology & Oncology 13 (1): N.PAG. doi:10.1186/s13045-020-00989-w.